Reply:
Laura Mensa, Sofia Perez‐del‐Pulgar, Xavier Forns – 22 June 2012
Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation
Jung Pyo Lee, Hyuk Yong Kwon, Ji In Park, Nam‐Joon Yi, Kyung‐Suk Suh, Hae Won Lee, Myounghee Kim, Yun Kyu Oh, Chun Soo Lim, Yon Su Kim – 19 June 2012 – Liver transplantation (LT) is the treatment of choice for hepatorenal syndrome (HRS). However, the clinical benefits of living donor liver transplantation (LDLT) are not yet well established. We, therefore, investigated the outcomes of patients with HRS who underwent LDLT and patients with HRS who received transplants from deceased donors.
Living donor liver transplantation for acute liver failure: No other choice
Chung‐Mau Lo – 19 June 2012
Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype
Milan J. Sonneveld, Willem P. Brouwer, Harry L.A. Janssen – 18 June 2012
Jaundice increases the rate of complications and one‐year mortality in patients with hypoxic hepatitis
Bernhard Jäger, Andreas Drolz, Barbara Michl, Peter Schellongowski, Andja Bojic, Miriam Nikfardjam, Christian Zauner, Gottfried Heinz, Michael Trauner, Valentin Fuhrmann – 18 June 2012 – Hypoxic hepatitis (HH) is the most frequent cause of acute liver injury in critically ill patients. No clinical data exist about new onset of jaundice in patients with HH. This study aimed to evaluate the incidence and clinical effect of jaundice in critically ill patients with HH. Two hundred and six consecutive patients with HH were screened for the development of jaundice during the course of HH.
Another drug in the armamentarium to combat hepatitis B virus in adolescents
Philip Rosenthal – 18 June 2012
Pathophysiological relevance of neutrophils in acetaminophen hepatotoxicity
Hartmut Jaeschke, Mitchell R. McGill, C. David Williams – 18 June 2012
Liver specific inactivation of carboxylesterase 3/triacylglycerol hydrolase decreases blood lipids without causing severe steatosis in mice
Jihong Lian, Enhui Wei, Shu Pei Wang, Ariel D. Quiroga, Lena Li, Alba Di Pardo, Jelske van der Veen, Simonetta Sipione, Grant A. Mitchell, Richard Lehner – 18 June 2012 – Carboxylesterase 3/triacylglycerol hydrolase (Ces3/TGH) participates in hepatic very low‐density lipoprotein (VLDL) assembly and in adipose tissue basal lipolysis. Global ablation of Ces3/Tgh expression decreases serum triacylglycerol (TG) and nonesterified fatty acid levels and improves insulin sensitivity.
Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents
Heiner Wedemeyer, Donald M. Jensen, Eliot Godofsky, Nina Mani, Jean‐Michel Pawlotsky, Veronica Miller, on behalf of the Definitions/Nomenclature Working Group* of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research – 18 June 2012 – Outdated virological response terms used at key trial timepoints in clinical trials with first‐generation direct‐acting antivirals plus pegylated interferon and ribavirin have failed to keep pace with hepatitis C virus (HCV) drug development.
HNF1B deficiency causes ciliary defects in human cholangiocytes
Philip Roelandt, Aline Antoniou, Louis Libbrecht, Werner Van Steenbergen, Wim Laleman, Chris Verslype, Schalk Van der Merwe, Frederik Nevens, Rita De Vos, Evelyne Fischer, Marco Pontoglio, Frédéric Lemaigre, David Cassiman – 18 June 2012 – Heterozygous deletion or mutation in hepatocyte nuclear factor 1 homeobox B/transcription factor 2 (HNF1B/TCF2) causes renal cyst and diabetes syndrome (OMIM #137920). Mice with homozygous liver‐specific deletion of Hnf1β revealed that a complete lack of this factor leads to ductopenia and bile duct dysplasia, in addition to mild hepatocyte defects.